Platelet RNA Expression Directs Identification of Clear Tumorprogression in Glioblastoma

• Conditions: glioblastoma; malignant brain tumor; 10029211

• Registration Number: NL-OMON56789
• Lead Sponsor: Amsterdam UMC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 190

Inclusion Criteria

Radiologic suspicion of high grade glioma on MRI
Eligible for resection
Older than 18 years of age
Dutch speaking

Exclusion Criteria

Known malignancy elsewhere in the body

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The difference in platelet RNA profile between blood taken at true progression<br /><br>and blood taken at pseudoprogression/radionecrosis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Established clinical prognostic factors and TEP-Glioblastoma-score will be<br /><br>analyzed in univariate and multivariate models of progression free and overall<br /><br>survival. Also, the effect of temozolomide and radiotherapy on the platelet RNA<br /><br>profiles will be evaluated by comparing groups of samples collected at moment<br /><br>of these therapies, and at moments when these therapies are not provided.<br /><br>In addition, the tumor size will be correlated to the TEP-Glioblastoma-score,<br /><br>and the levels of individual platelet RNAs.<br /><br>Finally, gene ontology analyses will be performed, aiming to elucidate involved<br /><br>molecular pathways in the platelets as a response to the intracranial tumor<br /><br>status, including DAVID GO, and PANTHER GO, as described and performed by us<br /><br>previously.</p><br>